A recent article in Engineering describes the development of a protein-based nanocomposite hydrogel designed to deliver two therapeutic agents—dexamethasone (Dex) and kartogenin (KGN)—to support cartilage repair. The hydrogel is engineered to modulate immune responses and promote the formation of cartilage tissue through controlled drug release.
Background
Cartilage has a limited ability to repair itself due to its avascular nature, which restricts nutrient flow and cell migration. Various scaffold materials, including natural polymers and composites, have been tested for cartilage repair. However, many of these face limitations such as poor mechanical strength, weak cell signaling, and inconsistent drug delivery.
Hydrogels are promising in this context because they are hydrophilic, biodegradable, and can mimic the properties of natural tissue. Designing hydrogels that coordinate immune regulation and tissue regeneration, however, remains a complex challenge.
Dexamethasone is a corticosteroid with strong anti-inflammatory effects. It can shift macrophages toward an M2 phenotype, which supports tissue repair. Kartogenin is a small molecule known to stimulate mesenchymal stem cells (MSCs) to differentiate into chondrocytes, enhancing cartilage formation. Combining both agents in a single hydrogel aims to first reduce inflammation and then encourage cartilage regeneration.
The Current Study
Researchers created a silk fibroin-based nanocomposite hydrogel loaded with Dex and KGN. KGN was covalently linked to silk proteins to form nanospheres (SPNs) that release the drug over time. Dex was incorporated non-covalently via hydrogen bonding with the silk matrix, forming a Dex-HLC complex intended for rapid release.
The hydrogel network was stabilized using enzymatic crosslinking with transglutaminase, which promoted covalent bonding between amino acid residues in the silk fibroin. This structure allowed for staged drug release: Dex would be released early to manage inflammation, and KGN would be released gradually during the tissue regeneration phase.
The hydrogel’s physical and chemical properties—such as strength, degradation rate, and drug release behavior—were assessed through spectroscopy, degradation studies, and release tests. Cytocompatibility was evaluated using cultures of MSCs and macrophages to monitor adhesion, growth, and differentiation.
An in vivo rabbit model of cartilage defect was used to test the hydrogel’s repair performance. After implantation, tissue samples were evaluated through histological staining (H&E, Safranin O), immunohistochemistry for inflammation and cartilage markers, and micro-CT imaging to assess cartilage and bone formation.
Results and Discussion
The hydrogel formed a stable and elastic structure with mechanical properties similar to native cartilage. It degraded at a rate aligned with typical cartilage healing timelines. In early-stage testing, Dex was released quickly and reduced inflammation, as shown by lower levels of cytokines such as TNF-α and IL-6. Macrophage analysis showed a shift from the M1 (inflammatory) to M2 (anti-inflammatory) phenotype after Dex exposure.
KGN was released over a longer period, supporting the differentiation of MSCs into chondrocytes. This was confirmed by increased expression of markers like type II collagen, SOX-9, and aggrecan. At the same time, expression of hypertrophy-associated markers like RUNX2 decreased, while RUNX1 expression increased, indicating stable chondrogenic differentiation and reduced risk of cartilage overgrowth.
In the rabbit model, defects treated with the hydrogel showed significant formation of hyaline-like cartilage, with organized extracellular matrix and tissue structures resembling native cartilage. These regions showed higher levels of cartilage matrix components and new bone formation compared to control groups. Immunohistochemical staining revealed reduced inflammatory signaling and increased collagen type II levels, confirming tissue regeneration with limited inflammation and hypertrophy.
Conclusion
This study describes a dual-drug nanocomposite hydrogel for cartilage repair that delivers Dex for early inflammation control and KGN for long-term cartilage regeneration. The material showed favorable mechanical performance, cell compatibility, and regenerative effects in a rabbit cartilage defect model. The combination of immune modulation and support for chondrogenesis represents a comprehensive strategy for tissue engineering.
While initial results are encouraging, further research is needed to refine drug delivery profiles, evaluate long-term outcomes, and confirm safety in larger animal models. This approach highlights the potential of responsive hydrogel systems in addressing challenges in cartilage repair and osteoarthritis treatment.
Journal Reference
Lei, H., Fan, D. (2025). Dual drug delivery nanocomposite hydrogel for cartilage repair: immunomodulation and chondrogenesis. Engineering. DOI: 10.1016/j.eng.2025.05.010, https://www.sciencedirect.com/science/article/pii/S2095809925002875?via%3Dihub
News
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
